I wouldn't make too large a deal of Fran Heller's departure. She's had a foot out the door - so to speak - since she accepted a director's position at Adimab last April. Since EXEL's focus has shifted solely to advancement of CABO, Fran's marketing position has been replaced by the clinical results that will ultimately drive the CABO franchise. Not much need for a cartographer once the planet is mapped. GLTA B
Yeah, I'm not sure how significant it is. It's just that I would have expected someone like Hellar to see an acquisition process through to the end. I was wondering if maybe she had something lined up, but it was rejected by the board, and she got fed up and walked. Could be a vote of confidence in Cabo if the board feels they can make it on their own (i.e. independent, non-aqcuisition route)... or just a lot of risk at shareholder expense.